Rockwell Medical, Inc. · NASDAQ:RMTI
Rockwell Medical — Investor Presentation (November 2025)
17 slides from Rockwell Medical's investor presentation, Nov 12, 2025
Slide 1: Rockwell Medical Investor Presentation
@) OC) ROCKWELL MEDICAL Investor Presentation November 12, 2025 RMTI
Slide 2: Forward-Looking Statements and Non-GAAP Measures
Forward-Looking Statements and Non-GAAP Measures Certain statements in this presentation may constitute "forward-looking statements" within the meaning of federal securities laws, including, but not limited to, Rockwell's expectations regarding revenue, profitability, financial position, 2024, 2025
Slide 3: Rockwell Medical At A Glance
Rockwell Medical At A Glance Healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. : Largest supplier of liquid bicarbonate hemodialysis concentrates in the U.S. Overview Second largest supplier of acid
Slide 4: Executive Management Team
Executive Management Team lent and Chief Executive Officer Dr. Mark Strobeck AASSERTIO= Aqulo @ (%) SR One Chief Financial Officer Jesse Neri ARUVANT btb<l bad Symphony Health Zylam Chief Legal Officer Megan Timmins aramark 3 AASSERTIO= Zylam ©2025 Rockwell Medical, inc. Chief Commercial Officer Tim
Slide 5: Corporate Strategy
Corporate Strategy = Ce) Provide Customers with the Diversify our Customer Optimize our Business through Achieve Sustainable Highest Quality and Most Base and Product Portfolio Continued Manufacturing Profitability Reliable Products and Services Improvements ©2025 Rockwell Medical, inc. © ROCKWELL M
Slide 6: Leading Manufacturer and Supplier of Concentrates
Leading Manufacturer and Supplier of Concentrates Hemodialysis is a Necessity for End Stage Renal Disease Patients Approximately 475,000 patients in the U.S. require in-center hemodialysis annually). Each patient receives approximately 3 treatments per week, totaling ~150 in-clinic procedures per pa
Slide 7: U.S. In-Center and Acute Care Hemodialysis Concentrates TAM
U.S. In-Center and Acute Care Hemodialysis Concentrates TAM ~4-6% CAGR driven primarily by increasing number of patients suffering from end-stage kidney disease 3 2024 2028 SOURCE: CAGR based on "Rockwell Medical: Concentrates Growth Strategy Report”, L.E.K. Consulting LLC (2022) (©2025 Rockwell Med
Slide 8: Sample of Dialysis Providers, Hospital Systems, Distributors that Rockwell Services
Sample of Dialysis Providers, Hospital Systems, Distributors that Rockwell Services Dialysis Providers Hospital Systems UPMC HCA+ Healthcare SANF3RD' pe BeylorSconestWhite HEALTH > Renalare CONCERTO) Greenfield Health Systems MAYO CLINIC LS weesews = Dalita Avrak WO v Intermountain: Healthcare fenia
Slide 9: Rockwell Distributes to 30+ Countries Worldwide
Rockwell Distributes to 30+ Countries Worldwide | Current Geographic Footprint || Current Expansion Opportunities (©2025 Rockwell Medical, inc. (ROCKWELL MEDICAL
Slide 10: Key Drivers to Diversify our Customer Base and Product Portfolio
Key Drivers to Diversify our Customer Base and Product Portfolio Geographic Expansion Increase market share throughout the U.S. oho and internationally. Rockwell continues to secure commercial partnerships and seeks additional growth opportunities globally. At Home Treatments At home dialysis and tr
Slide 11: Financials and Milestones
(ROCKWELL MEDICAL Financials and Milestones
Slide 12: Third Quarter 2025 Financial Results
Third Quarter 2025 Financial Results Three Months Ended September 30 (in Thousands, Except Per Share Amounts) Net Sales $ 15,927 $ 28,316 Gross Profit 2,272 6,239 Operating Income (Loss) (1,584) 1,936 Net Income (Loss) (1,753) 1,664 Adjusted EBITDA™ 50 2,798 Basic Net Income (Loss) per Share” $ (0.0
Slide 13: 2025 Guidance
2025 Guidance = | Ce] al Net Sales Adjusted EBITDA Gross Margin $65.0M - $70.0M $(0.5)M - $0.5M 16% to 18% al estimated that it wil loze approximately $36 mil he *Customer") tranations to another supplier. The Company i til i ts t2 Rockwell Medica While there can be ra 335 suceessfu cutcame for Rock
Slide 14: 2025 Projected Milestones
2025 Projected Milestones Achieve sustained profitability for FY’25 on an adjusted EBITDA basis. Grow concentrates business by adding new customers. Expand contracts and partnerships with existing customers. Continue to optimize our business through improved processes and expanded automated manufact
Slide 15: Why Invest in Rockwell Medical?
Why Invest in Rockwell Medical? v Experienced Management Team v Large and Growing Market Opportunity Y¥ Revenue-Generating Business v Strong Financials Y Attractive Valuation | RMTI canis pecan Meso, he UAT
Slide 16: Rockwell Medical
(© ROCKWELL MEDICAL www.rockwellmed.com IR@rockwellmed.com
Slide 17: Reconciliation to GAAP Financial Measures
Reconciliation to GAAP Financial Measures Non-GAAP Financial Measures To supplement the Company's financial results presented on a U.S. generally accepted accounting principles ("GAAP") basis, the Company has included information about non-GAAP measures of EBITDA and adjusted EBITDA 2s useful operat
Rockwell Medical — Investor Presentation (November 2025) on 6ix